Regenerative Medicine

IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services for the life sciences industry. With a mission to accelerate innovation for a healthier world and a vision to power smarter healthcare for everyone, everywhere, IQVIA leverages unparalleled data, transformative technology, and deep healthcare expertise to drive better patient outcomes. Operating in over 100 countries with approximately 88,000 employees, IQVIA supports pharmaceutical, biotech, medtech, public health, and government organizations with a comprehensive portfolio of services and solutions. The company is recognized for its Connected Intelligence™, healthcare-grade AI, and commitment to sustainability, innovation, and evidence-based insights that shape the future of healthcare globally. IQVIA is also dedicated to reducing health inequities and driving sustainable change through innovation, collaboration, and data-driven solutions, partnering with organizations worldwide to address complex healthcare challenges.

The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization dedicated to advancing the bioeconomy of the United States. Its mission encompasses enhancing manufacturing, healthcare, and education and workforce development, aiming to create a scalable and effective manufacturing ecosystem for engineered cells, tissues, and organs.

Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.

FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.

Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.

NervGen Pharma Corp is a clinical-stage biotech company focused on developing innovative treatments to enable nervous system repair in cases of traumatic injury and disease. Their lead drug candidate, NVG-291, is currently being evaluated in a Phase 1b/2a clinical trial for spinal cord injury, with additional preclinical evaluations for conditions such as ischemic stroke and amyotrophic lateral sclerosis (ALS). The company is also advancing a new development candidate, NVG-300, in preclinical studies.

VirTech Bio is an early-stage biotechnology company based in Natick, Massachusetts, focused on developing a human-derived hemoglobin-based oxygen carrier (HBOC) for use as a temporary blood substitute in trauma and transplantation. The company leverages expertise in hemoglobin polymerization to address critical needs in emergency medicine and organ preservation, with a pipeline also targeting veterinary and research applications. Process innovations allow scalable and contract-based manufacturing, supported by significant non-dilutive funding from the US Department of Defense and private investment.

Maverick Labs is a U.S.-based biotechnology and materials science company specializing in advanced protein design, synthetic biology, and microbial engineering. The company operates through three tightly integrated subsidiaries—Maverick Metals, Maverick Energy, and the Maverick Bio-Gene Therapy Translational Unit—each of which applies a shared technological foundation to tackle critical challenges across national defense, energy independence, and strategic material access. Together, they develop scalable, field-ready solutions that reinforce the United States’ industrial resilience and military readiness through biotechnology-driven innovation.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.

The American Burn Association (ABA) is a multidisciplinary organization dedicated to improving the lives of those affected by burn injury. With over 3,000 members worldwide, ABA focuses on promoting and supporting burn-related care, prevention, education, and research. The association brings together professionals from various disciplines to advance quality care, advocate for prevention, provide educational resources, and foster research in the field of burn injuries. ABA is also recognized for its leadership in advocacy, professional development, and the establishment of best practices and guidelines for burn care. The ABA regularly hosts conferences, develops clinical guidelines, and partners with organizations to raise awareness and improve outcomes for burn survivors.

Pulsara is a purpose-driven healthcare technology company focused on improving the lives of patients and caregivers through innovative, real-time communication and collaboration. Their telehealth platform connects clinicians, EMS, hospitals, and emergency management teams on a single patient channel, enabling dynamic, scalable, and secure care coordination for any illness or injury. Pulsara's evidence-based solutions are designed to reduce treatment times, lower costs, and enhance experiences for both patients and providers. The company is recognized for its customer-first values, award-winning support, and commitment to privacy, security, and interoperability.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

SanaHeal is dedicated to developing next-generation bioadhesive technologies inspired by nature to solve significant challenges in healthcare. Their innovative solutions are designed to adhere to wet and uneven surfaces, providing rapid and robust adhesion for various medical applications.

SERDA Therapeutics is a clinical stage biopharmaceutical company focused on developing innovative solutions for wound care, particularly in the treatment of burn injuries and chronic ulcers. The company aims to provide fast and effective therapeutic debridement through its proprietary enzymatic product, SN514, which is designed to enhance healing by selectively removing necrotic tissue.

Sonogen Medical Inc. is dedicated to researching, developing, and commercializing next-generation ultrasonic bone fracture healing technology. The company combines expertise in fluid mechanics, biophysics, sonar, and medical ultrasound to create safe and effective devices for bone healing.

The Institute for Integrative & Innovative Research (I3R) at the University of Arkansas is dedicated to pioneering solutions to complex societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I3R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.